Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 69-74

  Blanes, Margarita ^a,b   Lahuerta, Juan J ^c   González, José D ^d   Ribas, Paz ^e   Solano, Carlos ^f   Alegre, Adrían ^g   Bladé, Joan ^h   San Miguel, Jesús F ⁱ   Sanz, Miguel A ^a   De La Rubia, Javier ^a,j  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

more..

Author keywords

Autologous transplantation; Intravenous busulfan; Melphalan; Multiple myeloma

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871921174     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.009     Document Type: Article

References (39)

1. Harousseau J.L. Autologous transplantation for multiple myeloma. Ann Oncol 2008, 19(Suppl 7):128-133.
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
3. Child J.A., Morgan G.I., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
4. Harousseau J.L., Moreau P., Attal M., Facon T., Avet-Loiseau H. Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2005, 18:603-618.
5. Ludwig H., Beksac M., Bladé J., et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15:6-25.
6. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731-735.
7. Kyle R.A. Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia 2005, 19:910-912.
8. Barlogie B., Jagannath S., Naucke S., et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998, 21:1101-1107.
9. Mansi J., da Costa F., Viner C., Judson J., Gore M., Cunningham D. High-dose busulfan in patients with myeloma. J Clin Oncol 1992, 10:1569-1573.
10. Alegre A., Lamana M., Arranz R., et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995, 91:380-386.
11. Besinger W.I., Rowley S.D., Demirer T., et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996, 14:1447-1456.
12. Benson D.M., Elder P.J., Lin T.S., et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimen for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007, 31:1069-1075.
13. Anagnostopoulos A., Aleman A., Ayers G., et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004, 100:2607-2612.
14. Kazmi S.M., Saliba R.M., Donato M., et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 2011, 46:510-515.
15. Anderson K.C., Shaughnessy J.D., Barlogie B., Harousseau J.L., Rodman G.D. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002, 214-240.
16. Bladé J., Rosiñol L., Cibeira M.T., Rovira M., Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010, 115:3655-3663.
17. Lahuerta J.J., Martínez-López J., Grande C., et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000, 109:138-147.
18. Lahuerta J.J., Grande C., Blade J., et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 2002, 43:67-74.
19. Carreras E., Rosiñol L., Terol M.J., et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007, 13:1448-1454.
20. Lahuerta J.J., Mateos M.V., Martínez-López J., et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM200 study. Haematologica 2010, 95:1913-1920.
21. Blanes M., de la Rubia J., Lahuerta J.J., et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009, 50:216-222.
22. Gutiérrez N.C., Castellanos M.V., Martín M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007, 21:143-150.
23. Lahuerta J.J., Mateos M.V., Martínez-López J., et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26:5775-5782.
24. Rosiñol L., Pérez-Simón J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
25. Martínez-Sánchez P., Montejano L., Sarasquete M.E., et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 2008, 142:766-774.
26. Paiva B., Vidriales M.B., Cerveró J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
27. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
28. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988, 6:1562-1568.
29. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
30. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autograft myeloma. J Clin Oncol 2010, 28:2077-2084.
31. Kořen J., Spička I., Straub J., et al. Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre. Prague Med Rep 2010, 111:207-218.
32. Sirohi B., Powles R., Metha J., et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant 2005, 36:19-24.
33. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495-2502.
34. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
35. 2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area. Hematol Rev 2009, 1:9-13.
36. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109:3489-3495.
37. Kebriaei P., Madden T., Kazerooni R., et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011, 17:412-420.
38. Roussel M., Moreau P., Huynh A., et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010, 115:32-37.
39. Moreau P., Avet-Loiseau H., Harousseau J.L., Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011, 29:1898-1906.